PR95838

BANGKOK, May 6, 2022 /PRNewswire=KYODO JBN/ --

-- Strong evidence shows continued long-term lens effectiveness in slowing

myopia progression in children

HOYA Vision Care (

https://c212.net/c/link/?t=0&l=en&o=3525428-1&h=2929097389&u=https%3A%2F%2Fwww.hoyavision.com%2F&a=HOYA+Vision+Care

), a leader in optical technology innovation, shared the results of a six-year

follow-up clinical study (

https://c212.net/c/link/?t=0&l=en&o=3525428-1&h=3417434965&u=https%3A%2F%2Fwww.hoyavision.com%2Fabstract-6-years-result&a=six-year+follow-up+clinical+study

) on its award winning MiYOSMART spectacle lens with Defocus Incorporated

Multiple Segments (D.I.M.S.) Technology at the Association for Research in

Vision and Ophthalmology (ARVO) 2022 conference in Denver, Colorado in the U.S.

The findings, of the longest study on a myopia management spectacle lens, were

shared by Professor Carly Lam from the Centre for Myopia Research at The Hong

Kong Polytechnic University who conducted the research.

The results of the six-year clinical tudy conducted on 90 children in Asia

looked at the progression of myopia in children who wore the HOYA Vision Care's

MiYOSMART spectacle lens. The results enhanced a previous three-year follow-up

study(1), a continuation of a two-year randomized control trial (RCT)(2), which

was published in the British Journal of Ophthalmology, demonstrating strong

evidence of the lenses' effectiveness in slowing down the progression of myopia

in children ages 8-13. The findings of the six-year, long-term follow-up study

proved the MiYOSMART spectacle lens myopia control effect is sustained over

time for children wearing the lens. It also confirmed that patients who stop

wearing the MiYOSMART spectacle lens show no rebound effects when compared to

the initial myopia rates of progression during the two-year randomized control

trial or with the general population.

"This six-year follow-up clinical study on the MiYOSMART spectacle lens, the

longest study conducted on a myopia management spectacle lens ever, shows the

myopia control effects are sustainable over time which is very exciting news,"

said Natalia Vlasak, Global head of Medical and Scientific Affairs at HOYA

Vision Care. "This study also answered another key question from eye care

professionals which was about the rebound effect of the lens - we are very

pleased that this clinical study proves that there is no rebound effect if lens

use is stopped." "HOYA Vision Care is dedicated to being a leader in developing

a safe, effective way to manage the growing problem of myopia in children," she

added.

Launched in 2018, the MiYOSMART spectacle lens was developed in cooperation

with The Hong Kong Polytechnic University to address myopia, or near

sightedness which is a growing global health concern with industry experts

predicting nearly 50% of the world's population to be impacted by 2050.(3) The

lens uses D.I.M.S. Technology that provides children with sharp vision, can be

placed in any children's eyeglass frame and appears as a standard spectacle

lens. Since 2018, one million patients in more than 30 countries have benefited

from wearing the MiYOSMART spectacle lens.(4)

(1) Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus

incorporated multiple segments (DIMS) spectacle lens in Chinese children:

results of a 3-year follow-up study. British Journal of Ophthalmology Published

Online First: 17 March 2021. doi: 10.1136/bjophthalmol-2020-317664

(2) Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T,

To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow

myopia progression: a 2-year randomized clinical trial. British Journal of

Ophthalmology. Published Online First: 29 May 2019. doi:

10.1136/bjophthalmol-2018-313739

(3) Holden B.A., Fricke T.R., Wilson D.A., Jong M., Naidoo K.S., Sankaridurg

P., Wong T.Y., Naduvilath T.J., Resniko_ S. Global Prevalence of Myopia and

High Myopia and Temporal Trends from 2000 through 2050. American Academy of

Ophthalmology. 05/2016, vol.123, no. 5, p.1036–1042.

(4) Based on # lenses sold per Hoya sales data on file as of February 2022.

Individual wearer results may vary.

PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in

all countries, including the U.S., and is not currently available for sale in

all countries, including the U.S.

About HOYA Vision Care

For over 60 years, HOYA Vision Care has been a passionate and global leader in

optical technology innovation. As a manufacturer of high quality, high

performing eyeglass lenses, HOYA continues to drive optical technology

innovation with the aim of finding the best vision care solutions for Eye Care

Professionals. The company supplies lenses in 52 countries with a network of

over 18,000 employees and 45 laboratories around the globe.

SOURCE HOYA Vision Care

CONTACT: HOYA Vision Care PR Contact, Susan Brown, susan@wearenomads.com,

Mobile: +1 831 233 4616